Clincosm LogoSign in Get a demo

CLLTRegistry: Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study

Sponsor
Fatih Demirkan, MD (Other)
Overall Status
Recruiting
CT.gov ID
NCT03197259
Collaborator
(none)
1,000
Enrollment
1
Location
115
Anticipated Duration (Months)
8.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A prospective, multicenter national observational study for patients diagnosed as chronic lymphocytic leukemia across 25 centers in Turkey

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The purpose of this study is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employed in both the community and academic settings.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    1000 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Turkish Chronic Lymphocytic Leukemia Study Group Registry - Multicenter Prospective Study
    Actual Study Start Date :
    Jan 1, 2017
    Anticipated Primary Completion Date :
    Jan 1, 2023
    Anticipated Study Completion Date :
    Aug 1, 2026

    Outcome Measures

    Primary Outcome Measures

    1. First line therapy therapy protocol distrubition [36 months]

      The primary objective is to describe percentage of first line therapy protocols in patients initiated on therapy for CLL in the community and academic setting

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Patients diagnosed as CLL

    • 18 years or older

    • Able and willing to provide the written informed consent

    Exclusion Criteria:
    • Younger than 18 years

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dokuz Eylum Medical Favulty Izmir Turkey

    Sponsors and Collaborators

    • Fatih Demirkan, MD

    Investigators

    • Principal Investigator: Fatih Demirkan, Prof, Dokuz Eylum Medical Faculty

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Fatih Demirkan, MD, Board member, Izmir Hematologic Diseases and Cancer Research Help Association
    ClinicalTrials.gov Identifier:
    NCT03197259
    Other Study ID Numbers:
    • CLL TR Registry
    First Posted:
    Jun 23, 2017
    Last Update Posted:
    Mar 9, 2021
    Last Verified:
    Mar 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Fatih Demirkan, MD, Board member, Izmir Hematologic Diseases and Cancer Research Help Association
    CLL, del(17p)
    Additional relevant MeSH terms:
    Leukemia
    Leukemia, Lymphoid
    Leukemia, Lymphocytic, Chronic, B-Cell

    Study Results

    No Results Posted as of Mar 9, 2021